Cargando…

Different renoprotective effects of luseogliflozin depend on the renal function at the baseline in patients with type 2 diabetes: A retrospective study during 12 months before and after initiation

AIMS: The safety and efficacy, particularly, the factors associated with the renal prognosis, were assessed over 12 months after the initiation of luseogliflozin therapy in Japanese patients with type 2 diabetes and renal impairment. METHODS: In total, 238 patients treated with luseogliflozin (2.5 m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ito, Hiroyuki, Matsumoto, Suzuko, Izutsu, Takuma, Kusano, Eiji, Kondo, Jiro, Inoue, Hideyuki, Antoku, Shinichi, Yamasaki, Tomoko, Mori, Toshiko, Togane, Michiko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7959360/ https://www.ncbi.nlm.nih.gov/pubmed/33720983 http://dx.doi.org/10.1371/journal.pone.0248577

Ejemplares similares

Changes in the estimated glomerular filtration rate and predictors of the renal prognosis in Japanese patients with type 2 diabetes: A retrospective study during the 12 months after the initiation of tofogliflozin
por: Ito, Hiroyuki, et al.
Publicado: (2023)

Constipation Is a Frequent Problem Associated with Vascular Complications in Patients with Type 2 Diabetes: A Cross-sectional Study
por: Ito, Hiroyuki, et al.
Publicado: (2022)

Comparison of the changes in the factors associated with the renal prognosis of non-elderly and elderly subjects treated with empagliflozin- a retrospective observation study in Japanese patients with type 2 diabetes
por: Ito, Hiroyuki, et al.
Publicado: (2019)

Relationship Between the Effect of Roxadustat and Comorbid Diabetes in Non-dialyzed Chronic Kidney Disease Patients: A Retrospective Observational Study
por: Ito, Hiroyuki, et al.
Publicado: (2023)

A comparison of the clinical courses of type 2 diabetic patients whose basal insulin preparation was replaced from insulin glargine 100 units/mL to insulin glargine biosimilar or 300 units/mL: a propensity score-matched observation study
por: Ito, Hiroyuki, et al.
Publicado: (2018)

Erratum for Early Improvement of Non-islet Cell Tumor Hypoglycemia by Chemotherapy Using Lenvatinib in a Case with Type 2 Diabetes and Hepatocellular Carcinoma Producing Big IGF-II
por: Izutsu, Takuma, et al.
Publicado: (2021)

Early Improvement of Non-islet Cell Tumor Hypoglycemia by Chemotherapy Using Lenvatinib in a Case with Type 2 Diabetes and Hepatocellular Carcinoma Producing Big IGF-II
por: Izutsu, Takuma, et al.
Publicado: (2020)

Comparison of the Renoprotective Effect of Febuxostat for the Treatment of Hyperuricemia between Patients with and without Type 2 Diabetes Mellitus: A Retrospective Observational Study
por: Ito, Hiroyuki, et al.
Publicado: (2016)

Secular Trends in the Clinical Characteristics of Type 2 Diabetic Patients With Severe Hypoglycemia Between 2008 and 2013
por: Ito, Hiroyuki, et al.
Publicado: (2016)

Current Metabolic Status Affects Urinary Liver-Type Fatty-Acid Binding Protein in Normoalbuminuric Patients With Type 2 Diabetes
por: Ito, Hiroyuki, et al.
Publicado: (2017)

The estimated GFR, but not the stage of diabetic nephropathy graded by the urinary albumin excretion, is associated with the carotid intima-media thickness in patients with type 2 diabetes mellitus: a cross-sectional study
por: Ito, Hiroyuki, et al.
Publicado: (2010)

Hyperuricemia Is Independently Associated with Coronary Heart Disease and Renal Dysfunction in Patients with Type 2 Diabetes Mellitus
por: Ito, Hiroyuki, et al.
Publicado: (2011)

Long-term effect of metformin on blood glucose control in non-obese patients with type 2 diabetes mellitus
por: Ito, Hiroyuki, et al.
Publicado: (2010)

Effects of switching from prandial premixed insulin therapy to basal plus two times bolus insulin therapy on glycemic control and quality of life in patients with type 2 diabetes mellitus
por: Ito, Hiroyuki, et al.
Publicado: (2014)

Hypertension resistant to antihypertensive agents commonly occurs with the progression of diabetic nephropathy in Japanese patients with type 2 diabetes mellitus: a prospective observational study
por: Ito, Hiroyuki, et al.
Publicado: (2012)

The Prevalence of the Risk Factors for Atherosclerosis among Type 2 Diabetic Patients Is Greater in the Progressive Stages of Chronic Kidney Disease
por: Ito, Hiroyuki, et al.
Publicado: (2013)

Mild anemia is frequent and associated with micro‐ and macroangiopathies in patients with type 2 diabetes mellitus
por: Ito, Hiroyuki, et al.
Publicado: (2010)

Treatment with the SGLT2 inhibitor luseogliflozin improves nonalcoholic steatohepatitis in a rodent model with diabetes mellitus
por: Qiang, Shirong, et al.
Publicado: (2015)

Effects of luseogliflozin treatment on hyperglycemia-induced muscle atrophy in rats
por: Xie, Keyu, et al.
Publicado: (2023)

Vildagliptin is Effective for Glycemic Control in Diabetic Patients Undergoing either Hemodialysis or Peritoneal Dialysis
por: Ito, Hiroyuki, et al.
Publicado: (2013)

Randomized, Controlled, Thorough QT/QTc Study Shows Absence of QT Prolongation with Luseogliflozin in Healthy Japanese Subjects
por: Kumagai, Yuji, et al.
Publicado: (2015)

Effect of Luseogliflozin on Heart Failure With Preserved Ejection Fraction in Patients With Diabetes Mellitus
por: Ejiri, Kentaro, et al.
Publicado: (2020)

Flow Mediated Dilatation Is Reduced with the Progressive Stages of Glomerular Filtration Rate and Albuminuria in Type 2 Diabetic Patients without Coronary Heart Disease
por: Ito, Hiroyuki, et al.
Publicado: (2015)

Renoprotective effects of garlic
por: Nasri, Hamid
Publicado: (2013)

Renoprotective effects of metformin
por: Nasri, Running Hamid
Publicado: (2013)

The renoprotective effects of sulodexide
por: Olde Engberink, Rik HG, et al.
Publicado: (2016)

Effects of luseogliflozin on estimated plasma volume in patients with heart failure with preserved ejection fraction
por: Nakashima, Mitsutaka, et al.
Publicado: (2021)

Influence of Luseogliflozin on Vaginal Bacterial and Fungal Populations in Japanese Patients With Type 2 Diabetes
por: Kusunoki, Masataka, et al.
Publicado: (2021)

Luseogliflozin inhibits high glucose-induced TGF-β2 expression in mouse cardiomyocytes by suppressing NHE-1 activity
por: Osaka, Naoya, et al.
Publicado: (2022)

The SGLT2 Inhibitor Luseogliflozin Rapidly Normalizes Aortic mRNA Levels of Inflammation-Related but Not Lipid-Metabolism-Related Genes and Suppresses Atherosclerosis in Diabetic ApoE KO Mice
por: Nakatsu, Yusuke, et al.
Publicado: (2017)

Renoprotection and the Bardoxolone Methyl Story – Is This the Right Way Forward? A Novel View of Renoprotection in CKD Trials: A New Classification Scheme for Renoprotective Agents
por: Onuigbo, Macaulay
Publicado: (2013)

Renoprotective effects of green tea
por: Hajian, Shabnam
Publicado: (2013)

Possible renoprotective effects of dabigatran
por: Karahan, Oğuz
Publicado: (2015)

Early renoprotection by anemia correction
por: Kuriyama, Satoru
Publicado: (2018)

Mineralocorticoid receptor blockade for renoprotection
por: Cha, Dae Ryong
Publicado: (2018)

Luseogliflozin reduces epicardial fat accumulation in patients with type 2 diabetes: a pilot study
por: Bouchi, Ryotaro, et al.
Publicado: (2017)

Luseogliflozin Additively Enhances the Glucose-Lowering Effect of an Incretin Modulator in a High-Carbohydrate Diet
por: Lee, Gendai
Publicado: (2022)

Additional Effect of Luseogliflozin on Semaglutide in Nonalcoholic Steatohepatitis Complicated by Type 2 Diabetes Mellitus: An Open-Label, Randomized, Parallel-Group Study
por: Miyake, Teruki, et al.
Publicado: (2022)

Effects of luseogliflozin on arterial properties in patients with type 2 diabetes mellitus: The multicenter, exploratory LUSCAR study
por: Kario, Kazuomi, et al.
Publicado: (2020)

Luseogliflozin preserves the pancreatic beta-cell mass and function in db/db mice by improving mitochondrial function
por: Yamauchi, Yuki, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_fbo65jl2n68pe32auq0ef2vdlu